• Explore /
  • Poster
  • / A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer.

A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer.

Abstract Poster

Authors

Evan Yu

Evan Y. Yu

Fred Hutchinson Cancer Research Center, Seattle, WA

Evan Y. Yu , Salim Yazji , Yisrael Katz , Elisabeth Coates , Luke T. Nordquist , Andrae Lavon Vandross , Mohamad Adham Salkeni , Joshua Michael Lang , Peter Nelson , James Bradley Breitmeyer , Lawrence Fong , Johann S. De Bono

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT 05917470

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr TPS241)

DOI

10.1200/JCO.2024.42.4_suppl.TPS241

Abstract #

TPS241

Poster Bd #

Q2

Abstract Disclosures

Similar Posters

First Author: Xiaolin Zhu

First Author: Aishwarya Subramanian

First Author: Arpit Rao

First Author: Arpit Rao